Ireland
--:--IST
Latest
Merck's Oral PCSK9 Pill Lipfendra: EU Review and Ireland FDA Tentatively Approves Dr Reddy's Generic Lenacapavir FDA Approves GSK's Hibsago for Chronic Hepatitis B in Adults Wegovy in Ireland: NCPE Backs It, HSE Decision Still Awaited GSK Q3 2026: Falling Vaccine Sales Dent a Strong Quarter Experic Wins HPRA Licence for Kilbeggan Trial Supply Site Merck's Oral PCSK9 Pill Lipfendra: EU Review and Ireland FDA Tentatively Approves Dr Reddy's Generic Lenacapavir FDA Approves GSK's Hibsago for Chronic Hepatitis B in Adults Wegovy in Ireland: NCPE Backs It, HSE Decision Still Awaited GSK Q3 2026: Falling Vaccine Sales Dent a Strong Quarter Experic Wins HPRA Licence for Kilbeggan Trial Supply Site
Clinical Trials in the UK / NCT05652439
Recruiting Observational

PASS to Assess Cardiovascular and Cerebrovascular Events in COPD Patients Initiating Fixed Triple Therapy (DPI or pMDI)

NCT05652439 · tracked via the Priya Life Science UK tracker
Sponsor
Chiesi Farmaceutici S.p.A
Phase
Observational
Started
2022-12-02
Last updated
2026-10-22

Condition(s) studied

Chronic Obstructive Pulmonary Disease

Investigational drug(s) / intervention(s)

Observational retrospective data collection

Observational retrospective data collection: Observational retrospective data collection of the incidence of adverse cardiovascular and cerebrovascular outcomes

Study summary

The aim of this Post Authorisation Safety Study (PASS) is to assess the incidence of adverse cardiovascular and cerebrovascular events in COPD patients who are new to inhaled fixed triple therapy (dual bronchodilator plus corticosteroid) administered via Dry Powder Inhaler (DPI) compared to new users of pressurized Metered Dose Inhaler (pMDI).

Data from clinical practice from different European data sources will be collected. The baseline hypothesis is that the DPI is not associated with different risks of the primary and secondary outcomes, compared with pMDI.

Eligibility

Sex
ALL
Min age
40 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients diagnosed with COPD * 40 years or older * Availability of baseline information for a minimum of 12 months before the index date * New users of single inhaler triple therapy BDP/FF/GB via DPI or pMDI Exclusion Criteria: * Single or multi-inhaler triple therapy in the previous 90 days before the index date * Prescription of BDP/FF/GP administered via pMDI or DPI or any other single inhaler triple therapy in addition to a study drug on the index date. * Hospitalization due to cardiovascular causes in the previous 30 days before the index date.

Primary outcome measure(s)

  • Incidence of Major Adverse Cardiovascular Events (MACE) — Through study completion, up to 5 years
    To assess the incidence of MACEs and compare it between fixed triple therapy BDP/FF/GB via DPI and pMDI formulation. MACEs will be defined as any of the following events: * Myocardial infarction * Stroke (ischemic and haemorrhagic stroke) * Hospitalization due to acute coronary syndrome * Hospitalization due to heart failure

Trial sites (1)

FacilityCityRegionStatus
Clinical Practice Research Datalink (CPRD) London United Kingdom Recruiting

More Chiesi Farmaceutici S.p.A. trials in the UK

Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma Recruiting
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease Recruiting
A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez Recruiting
A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients Recruiting
MEASuRE: Metreleptin Effectiveness And Safety Registry Recruiting

Other trials for the same condition

A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation Recruiting
A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD) Enrolling by invitation
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype Recruiting
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Active, not recruiting
Ryme Medical TLD Pilot Study Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05652439 on ClinicalTrials.gov ↗ ← All trials in the UK